{"id":"W4408682588","doi":"10.1177/17588359251326710","title":"Clinician’s guide: expert insights on the use of CDK4/6 inhibitors in patients with early breast cancer","year":2025,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Occupational Cancer Research Centre; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research; Novartis Pharmaceuticals Canada; Genentech; Astellas Pharma; Seagen; University of Toronto; Genomic Health; F. Hoffmann-La Roche; Purdue University; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Novartis; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Adverse effect; Discontinuation; Breast cancer; Adjuvant; Oncology; Clinical trial; Disease; Internal medicine; Cancer; Intensive care medicine; Quality of life (healthcare); Metastatic breast cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002541265,0.001158381,0.001496276,0.002926332,0.0009700236,0.00244828,0.001818197,0.006900106,0.09485975],"category_scores_gemma":[0.02752632,0.0005976608,0.001479549,0.001929091,0.0006797532,0.003576073,0.001898854,0.005998311,0.07635389],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001135729,"about_ca_system_score_gemma":0.003121915,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002742263,"about_ca_topic_score_gemma":0.007822144,"domain_scores_codex":[0.9981845,0.0005904767,0.000330175,0.0001735409,0.0005752358,0.0001460035],"domain_scores_gemma":[0.9886695,0.00428087,0.0006762987,0.000275294,0.004764668,0.001333426],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00002460339,0.00002881243,0.0001672434,0.0002828983,0.000005299485,0.0003831194,0.0000522649,0.00006690637,0.0001041113,0.0002486751,0.9187766,0.07985938],"study_design_scores_gemma":[0.00006457307,0.00004851664,0.0007126834,0.002062981,0.00001597695,0.003784716,0.0001914878,0.0001760759,0.00009976343,0.002286526,0.9905196,0.00003692955],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"review","genre_scores_codex":[0.001700829,0.1531892,0.02079436,0.5048536,0.0598279,0.001284155,0.005551086,0.005610583,0.2471883],"genre_scores_gemma":[0.01640848,0.2177853,0.05009248,0.4113824,0.07699011,0.002387497,0.00504687,0.001330216,0.2185766],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.09485975,"threshold_uncertainty_score":0.3173375,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05930661329680937,"score_gpt":0.4257630122102647,"score_spread":0.3664563989134554,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}